MedTrace Logo

Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

NCT04521179 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2023-09-21

No results posted yet for this study

Summary

This is an open-label, phase II，multi-center study to evaluate the efficacy, safety and tolerability of KN026 in combination with KN046 in subjects with HER2-positive solid tumors.

Conditions

  • HER2-positive Solid Tumors

Interventions

DRUG

KN026 combination

30 mg/kg Q3W KN026+ 5 mg/kg Q3W KN046

Sponsors & Collaborators

  • Peking University

    collaborator OTHER

  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Lin Shen, professor · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-07
Primary Completion
2022-01-12
Completion
2023-05-22

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04521179 on ClinicalTrials.gov